Abstract
Objective
The study tested whether cardiovascular corresponding LPA risk genotypes improve pre-eclampsia and coronary heart disease (CHD) risk prediction beyond conventional risk factors.
Background
Studies have shown that women specific risk factors for cardiovascular disease (CVD) have taken an attention recently. It might be possible to identify women who have the highest risk in developing CVD in their further lives. It is well-known that Lp(a) levels have an impact on increased risk of CVD which is affected by LPA gene. Further, LPA risk genotypes are not considered in cardiovascular risk prediction.
Methods
We have included 200 pregnant Turkish women into the study. We stratified the preeclamptic (PE) group: early (EOP) (28.7 ± 3.0 weeks) and late onset (LOP) (36.0 ± 1.4 weeks). 14 LPA SNPs were evaluated in the study. Rs9355296 and rs3798220 were found as independent risk factors for preeclampsia by logistic regression analysis. A positive correlation was found between rs9355296 and the diagnostic criteria of preeclampsia. Further rs9355296 G/* carriers have higher vascular inflammation rather than AA carriers.
Conclusions
The findings reveal that LPA genetic variability with high inflammatory response might be an indication of future cardiovascular events.
Disclosure statement
No potential conflict of interest was reported by the authors.
Ethical approval
The study protocol was previously reviewed and approved by the Ethics Committee of the University of Istanbul, Cerrahpasa Medical School (issue no. 16057, 5 June 2012). All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national Research Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.